Investigational drug · Phase 3
Seltorexant
Also called: JNJ 42847922
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Depressive Disorder, Major.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
33
Any phase or sponsor naming "Seltorexant"
First trial start
2024
Jul 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Seltorexant", any sponsor or status.
- Phase 123
Conditions studied
As listed on its trial records.
- Depressive Disorder, Major
Approved drugs for the same conditions: Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "Seltorexant" as an intervention, largest first.
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04513912 · 757 participants · Start Sep 15, 2020 · Primary completion Oct 3, 2023
Drug: Seltorexant; Matching placebo to Seltorexant and 2 more · For: Depressive Disorder, Major
Sites: Birmingham, Alabama; Tucson, Arizona; Culver City, California · 175 sites in all
- Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia SymptomsPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06559306 · 752 participants (planned) · Start Jul 25, 2024 · Primary completion Dec 30, 2026
Drug: Seltorexant; Placebo and 1 more · For: Depressive Disorder, Major
Sites: Birmingham, Alabama; Chandler, Arizona; Tucson, Arizona · 205 sites in all
- A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive DisorderPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07573176 · 600 participants (planned) · Start Apr 30, 2026 · Primary completion Aug 24, 2028
Drug: Seltorexant; Placebo · For: Depressive Disorder, Major
Sites: Bryant, Arkansas; Bellflower, California; Glendale, California · 53 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04533529 · 588 participants · Start Sep 16, 2020 · Primary completion Apr 25, 2023
Drug: Seltorexant; Placebo · For: Depressive Disorder, Major
Sites: Anaheim, California; Cerritos, California; Irvine, California · 122 sites in all
- A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia DisorderPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03375203 · 365 participants · Start Nov 23, 2017 · Primary completion Apr 3, 2019
Drug: Placebo; JNJ-42847922, 5 mg and 3 more · For: Insomnia Disorders
Sites: Little Rock, Arkansas; Rogers, Arkansas; Anaheim, California · 56 sites in all
- A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant TherapyPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03227224 · 287 participants · Start Aug 16, 2017 · Primary completion Jan 12, 2019
Drug: Placebo; JNJ-42847922 · For: Depressive Disorder, Major
Sites: Anaheim, California; Chino, California; Lemon Grove, California · 101 sites in all
- A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant TherapyPivotal-lookingTerminated
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04532749 · 212 participants · Start Sep 15, 2020 · Primary completion May 24, 2022
Drug: Seltorexant; Placebo · For: Depressive Disorder, Major
Sites: Phoenix, Arizona; Little Rock, Arkansas; Glendale, California · 80 sites in all
- A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy ParticipantsPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03682380 · 151 participants · Start Oct 1, 2018 · Primary completion Aug 23, 2019
Drug: Seltorexant High Dose; Seltorexant Low Dose · For: Healthy
Sites: Salt Lake City, Utah
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT02837692 · 140 participants · Start Jun 8, 2016 · Primary completion Sep 7, 2017
Drug: JNJ-42847922 10 milligram (mg); JNJ-42847922 20 mg and 2 more · For: Healthy
Sites: Cypress, California; Knoxville, Tennessee
- A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive DisorderPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT03374475 · 140 participants · Start Jan 5, 2018 · Primary completion Apr 29, 2019
Drug: JNJ-42847922 20mg; JNJ-42847922 40mg and 1 more · For: Depressive Disorder, Major
Sites: San Diego, California; San Marcos, California; Miami, Florida · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Lateral hypothalamic orexinVTA projection regulates consolation via orexin receptor 1 in male mice.
Tian J, Li WC, Zhang LY, et al. · Neuropharmacology 2027
- Evaluating seltorexant as a treatment option for major depressive disorder.
Di Nicola M, Pepe M, Marcelli I, et al. · Expert Rev Neurother 2026
- Pharmacologic modulation of orexin signaling: Impact on glucose-insulin homeostasis and potential mechanism of antidepressant action.
McIntyre RS, Wong S · CNS Spectr 2026
- Acute Sleep Deprivation in Adolescence Produces Transcriptional Changes in the Orexin System and Regulates Motivation for Reward.
Forbes C, Zeak J, Shelton M, et al. · Biol Psychiatry Glob Open Sci 2026
- Unveiling the binding mechanism of orexin 2 receptor antagonists with computational chemistry.
de Souza Sena CP, de Albuquerque PC, Fulco UL, et al. · Phys Chem Chem Phys 2026
- Safety, tolerability, and preliminary efficacy of seltorexant versus quetiapine extended release as adjunctive therapy in major depressive disorder: a randomized, flexible-dose, 6-month, parallel-group, exploratory study.
Pinter C, Thase ME, McIntyre RS, et al. · Int J Neuropsychopharmacol 2026
Also in development for Depressive Disorder, Major
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- BI 1569912Phase 22 trials
Boehringer Ingelheim · Depressive Disorder, Major
- JNJ-89495120Phase 21 trial
Johnson & Johnson (Janssen) · Depressive Disorder, Major
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.